Results of a study examining the combination of obinutuzumab, ibrutinib and venetoclax for mantle cell lymphoma.
Home / Resource Library / Addition of Obinutuzumab and Venetoclax to Ibrutinib Overcomes Resistance in R/R MCL, Shows Activity in Newly Diagnosed MCL